1. Clin Hematol Int. 2022 May 12;4(1-2):52-55. doi: 10.1007/s44228-022-00002-w. 
eCollection 2022 Jun.

Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context 
of Myelodysplasia Treated with Azacytidine.

Manzoni M(1), Bosi A(2)(3), Fabris S(2), Lionetti M(3), Salerio S(2), Migliorini 
AC(2), Cavallaro F(2)(3), Barbullushi K(2)(3), Rampi N(2)(3), Montefusco V(4), 
Alessio MG(5), Neri A(2)(3), Baldini L(2)(3), Sciumè M(2), Tagliaferri E(2), 
Fracchiolla N(2), Bolli N(2)(3).

Author information:
(1)Unità di Medicina II, ASST Santi Paolo e Carlo, Dipartimento di Scienze della 
Salute, Università degli Studi di Milano, Milan, Italy.
(2)Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore 
Policlinico, 20122 Milan, Italy.
(3)Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, 
Italy.
(4)Department of Onco-Hematology, ASST Santi Paolo e Carlo, Milan, Italy.
(5)Dipartimento di Analisi Cliniche, ASST Santi Paolo e Carlo, Milan, Italy.

DOI: 10.1007/s44228-022-00002-w
PMCID: PMC9358783
PMID: 35950209

Conflict of interest statement: Competing interestsThe authors declare that they 
have no competing interests.